Jan 8 (Reuters) - Acorda Therapeutics Inc:
* ACORDA ANNOUNCES 2017 AMPYRA NET SALES AND PROVIDES 2018 FINANCIAL GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE
* SEES FY 2018 SALES $330 MILLION TO $350 MILLION FOR AMPYRA
* INBRIJA NDA RESUBMITTED IN DECEMBER 2017; INITIAL FDA RESPONSE EXPECTED IN FEBRUARY 2018
* YEAR-END CASH BALANCE FOR 2018 IS PROJECTED TO BE OVER $300 MILLION Source text for Eikon: Further company coverage:
 